Recombinant Human ASGR2 protein

ASGR2 (asialoglycoprotein receptor 2) is a transmembrane protein belonging to the C-type lectin superfamily, predominantly expressed on the surface of hepatocytes. It plays a critical role in glycoprotein homeostasis by recognizing and binding to desialylated (galactose-terminal) glycoproteins, triggering their endocytosis and lysosomal degradation. This receptor forms a heteromeric complex with ASGR1. enhancing ligand-binding specificity and cellular uptake efficiency. ASGR2 has garnered significant interest in biomedical research due to its liver-specific expression and potential as a therapeutic target or drug delivery vehicle.

Recombinant ASGR2 proteins are engineered to study its structural and functional properties, often produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. These proteins typically include extracellular domains responsible for ligand interaction, fused with tags like Fc or His for purification and detection. Researchers utilize recombinant ASGR2 to investigate receptor-ligand interactions, screen targeted therapies, and develop liver-directed delivery systems for genes, drugs, or nanoparticles.

In clinical contexts, ASGR2 has been explored as a biomarker for liver diseases, including hepatocellular carcinoma and fibrosis. Its ability to mediate targeted internalization makes it valuable for designing ASGR2-binding ligands or antibodies in cancer therapy and antiviral strategies. Recent studies also examine its role in cholesterol metabolism regulation, potentially linking it to cardiovascular diseases. The development of recombinant ASGR2 continues to advance both basic research and translational applications in hepatology and precision medicine.